raloxifene hydrochloride has been researched along with piperidines in 277 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (12.64) | 18.7374 |
| 1990's | 199 (71.84) | 18.2507 |
| 2000's | 28 (10.11) | 29.6817 |
| 2010's | 14 (5.05) | 24.3611 |
| 2020's | 1 (0.36) | 2.80 |
| Authors | Studies |
|---|---|
| Gröner, I; McArdle, CA; Poch, A; Schomerus, E | 1 |
| Bern, HA; Chou, YC; Iguchi, T | 1 |
| Folse, DS; Liehr, JG; Roy, D | 1 |
| Chung, LW; Neubauer, BL; Petrow, V; Sikes, RA; Thomsen, S | 1 |
| Bern, HA; Hamamoto, ST; Tsai, PS; Uchima, FD | 1 |
| Banks, PK; Brodie, AM; Meyer, K | 1 |
| Gottardis, MM; Jordan, VC; Satyaswaroop, PG | 1 |
| de Launoit, Y; Dufour, M; Labrie, F; Simard, J; Veilleux, R | 1 |
| Geisert, RD; Morgan, GL; O'Neill, LA; Wettemann, RP; Zavy, MT | 1 |
| Bennett, JA; Bowser, SS; Bradley, L; Dickerman, HW; Gierthy, JF; Lincoln, DW; Roth, KE | 1 |
| Dauvois, S; Dumont, M; Hatton, AC; Labrie, C; Labrie, F; Mérand, Y; Poirier, D; Poulin, R; Simard, J; Zhao, HF | 1 |
| Boundy, V; Komm, BS; Lyttle, CR; Sundstrom, SA; Xu, Q | 1 |
| Beecham, GD; Snyder, BW; Winneker, RC | 2 |
| Couët, J; Dauvois, S; Dumont, M; Hatton, AC; Labrie, C; Labrie, F; Petitclerc, L; Poulin, R; Simard, J; Zhao, HF | 1 |
| Emons, G; Knuppen, R; Ortmann, O; Sturm, R | 1 |
| Biser, P; Goode, RL; Hoover, DM; Jones, CD; Mariotti, A; Neubauer, BL; Thornton, MO; Thornton, T | 1 |
| Bauss, F; Feldmann, S; Lempert, UG; Minne, HW; Parvizi, S; Pfeifer, M; Ziegler, R | 1 |
| Dufour, JM; Labrie, F; Levesque, C; Merand, Y; Poirier, D; Poulin, R | 1 |
| Barraclough, CA; Petersen, SL | 1 |
| Dauvois, S; Haagensen, DE; Hatton, AC; Labrie, C; Labrie, F; Simard, J; Zhao, HF | 1 |
| Labrie, F; Simard, J | 2 |
| Butcher, F; Durham, J; Frederickson, R; Mariotti, A; Mawhinney, M; Miller, R | 1 |
| Levinson, AI; Sanders, MC; Schreiber, AD | 1 |
| Catt, KJ; Knecht, M; Tsai-Morris, CH | 1 |
| Brodie, AM; Catt, KJ; Knecht, M | 1 |
| Hsueh, AJ; Kessel, B | 1 |
| Baker, D; Labrie, F; Poulin, R | 1 |
| Balakrishnan, A; Edery, M; Imagawa, W; Nandi, S; Richards, J | 1 |
| Catt, KJ; Emons, G; Knuppen, R; Ortmann, O | 1 |
| Bégin, D; Labrie, F; Luthy, IA | 1 |
| Buzdar, AU; Holmes, F; Hortobagyi, G; Hug, V; Marcus, C | 1 |
| Veldhuis, JD | 1 |
| Dohanich, GP; McEwen, BS; Meisel, RL; Pfaff, DW | 1 |
| Gottardis, MM; Jordan, VC | 1 |
| Banerjee, S; Finlay, TH; Katz, J; Levitz, M | 1 |
| Daniel, CW; Silberstein, GB; Strickland, P | 1 |
| Jordan, VC; Lindgren, JU; Phelps, E | 1 |
| Furlanetto, RW; Rodgers, RJ; Veldhuis, JD | 1 |
| Hubert, JF; Labrie, F; Vincent, A | 1 |
| Clark, GM; Hobbs, K; Osborne, CK | 1 |
| Bennett, DR; Black, LJ; Clemens, JA; Jones, CD | 1 |
| Jordan, VC | 7 |
| Black, LJ; Clemens, JA; Falcone, JF; Jevnikar, MG; Jones, CD; Peters, MK; Pike, AJ; Thompson, AR | 1 |
| Lindstrom, TD; Whitaker, GW; Whitaker, NG | 1 |
| Green, LR; Newboult, E; Valcaccia, B; Wakeling, AE | 1 |
| Babitsky, G; Kleinberg, DL; Todd, J | 1 |
| Valcaccia, B; Wakeling, AE | 1 |
| Black, LJ; Falcone, JF; Jones, CD | 1 |
| Best, KL; Counts, DF; Goode, RL; Hoover, DM; Jones, CD; Merriman, RL; Neubauer, BL; Sarosdy, MF; Shaar, CJ; Tanzer, LR | 1 |
| Fournier, B; Hall, TJ; Nyugen, H; Schaueblin, M | 1 |
| Bryant, HU; Cole, HW; Draper, MW; Fuchs-Young, R; Glasebrook, AL; Magee, DE; Rippy, MK; Short, LL; Termine, JD | 1 |
| Gabriel, SM; Koenig, JI; Washton, DL | 1 |
| Draper, MW; Flowers, DE; Huster, WJ; Neild, JA; Zerbe, RL | 1 |
| Bryant, HU; Kim, J; Sato, M; Short, LL; Slemenda, CW | 1 |
| Bryant, HU; Sato, M; Turner, CH | 1 |
| Bryant, HU; Kim, J; Magee, D; McClintock, C; Sato, M; Slemenda, CW; Turner, CH | 1 |
| Bryant, HU; Evans, G; Magee, D; Sato, M; Turner, RT | 1 |
| Jiang, SY; Jordan, VC; Parker, CJ | 1 |
| Best, KL; Clemens, JA; Gates, CA; Goode, RL; Hoover, DM; Jones, CD; Laughlin, ME; Neubauer, BL; Shaar, CJ; Toomey, RE | 1 |
| Güttinger, HR; Herth, G; Kafitz, KW; Kallenbach, M; Stocker, S | 1 |
| Bekele, A; Bendele, R; Bensch, WR; Black, LJ; Cullinan, GJ; Kauffman, RF; Magee, DE; Rowley, ER; Sato, M; Williams, DC | 1 |
| Hayes, TB; Licht, P; Tsai, PS | 1 |
| Anzano, MA; Brown, CC; Driver, CL; Logsdon, DL; Mullen, LT; Peer, CW; Roberts, AB; Shrader, MW; Smith, JM; Sporn, MB | 1 |
| Clemm, DL; Goldman, ME; Hermann, T; McDonnell, DP; Pike, JW | 1 |
| Arbell, A; Danilenko, M; Karas, M; Kleinman, D; LeRoith, D; Levy, J; Roberts, CT; Sharoni, Y | 1 |
| Bryant, HU; Galvin, RJ; Glasebrook, AL; Hardikar, S; Sato, M; Termine, JD; Yang, NN | 1 |
| Hoszowski, K | 1 |
| Bryant, HU; Rippy, MK; Sato, M | 1 |
| Lips, P; Netelenbos, JC | 1 |
| Glasebrook, A; Hardikar, S; Venugopalan, M; Yang, NN | 2 |
| Arnaud, C; Draper, MW; Flowers, DE; Harper, KD; Huster, WJ; Neild, JA | 1 |
| Ziegler, J | 1 |
| Pennisi, E | 1 |
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Bryant, HU; Evans, GL; Magee, DE; Turner, RT | 1 |
| Raisz, LG | 1 |
| Bemis, K; Bryant, HU; Burr, DB; Helterbrand, J; Higgs, R; Iversen, P; Owan, I; Sato, M; Smietana, F; Takano, Y; Turner, CH | 1 |
| Fournier, B; Häring, S; Kaye, AM; Sömjen, D | 1 |
| Bryan, N; Zuckerman, SH | 1 |
| Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C | 1 |
| Howlett, AC; Ruh, MF; Taylor, JA; Welshons, WV | 1 |
| Bean, JS; Bensch, WR; Bryant, HU; Cole, HW; Cullinan, GJ; Glasebrook, AL; Kauffman, RF; Monroe, A; Phillips, DL; Roudebush, RE | 1 |
| Adrian, MD; Bryant, HU; Cho, S; Cole, HW; Finley, DR; Glasebrook, AL; Godfrey, AG; Grese, TA; Jones, CD; Lugar, CW; Magee, DE; Martin, MJ; Matsumoto, K; Pennington, LD; Phillips, DL; Rowley, ER; Short, LL; Winter, MA | 1 |
| Kaye, AM; Sömjen, D; Waisman, A | 1 |
| Gradishar, WJ; Jordan, VC | 1 |
| Carver, JM; Lundeen, SG; McKean, ML; Winneker, RC | 1 |
| Cheskis, BJ; Karathanasis, S; Lyttle, CR | 1 |
| Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ | 1 |
| Logie, C; Nichols, M; Rientjes, JM; Stewart, AF | 1 |
| Cosman, F; Lindsay, R | 1 |
| Anthony, MS; Clarkson, TB; Cline, JM; Williams, JK | 1 |
| Rackoff, P | 1 |
| Smigel, K | 1 |
| Bélanger, A; Caron, B; Cloutier, J; Dory, YL; Favre, A; Gauthier, S; Labrie, C; Labrie, F; Larouche, D; Leblanc, G; Mailhot, J; Martel, C; Mérand, Y; Ouellet, C; Schwerdtfeger, A; Simard, J | 1 |
| Catherino, WH; Jordan, VC; Levenson, AS | 1 |
| Ashby, J; Foster, JR; Odum, J | 1 |
| Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM | 1 |
| Asplin, I; Baer, P; Brown, HR; Henke, B; Jones, SA; McDonnell, DP; Morris, DC; Norris, JD; Sauls, H; Wagner, BL; Willson, TM; Wolfe, S | 1 |
| Gustafsson, J; Kuiper, GG; Kushner, PJ; Nilsson, S; Paech, K; Scanlan, TS; Webb, P | 1 |
| Compston, JE | 2 |
| Bjarnason, NH; Byrjalsen, I; Christiansen, C; Haarbo, J; Kauffman, RF | 1 |
| Bryant, HU; Cho, S; Dodge, JA; Frolik, CA; Glasebrook, AL; Lugar, CW; Martin, MJ; Osborne, JJ; Phillips, DL; Sato, M; Short, LL; Spangle, LA; Yang, NN | 1 |
| Draper, MW; Heaney, RP | 1 |
| Bonn, T; Brzozowski, AM; Carlquist, M; Dauter, Z; Engström, O; Greene, GL; Gustafsson, JA; Hubbard, RE; Ohman, L; Pike, AC | 1 |
| Bryant, HU; Cox, MB; Draper, MW; Hol, T | 1 |
| Smith, TL | 1 |
| Andersson-Ross, C; Barkhem, T; Höglund, M; Nilsson, S | 1 |
| Bjarnason, NH; Christiansen, C; Delmas, PD; Draper, M; Huster, WJ; Mitlak, BH; Ravoux, AC; Shah, AS | 1 |
| Fuleihan, GE | 1 |
| Lane, MV; Merchenthaler, I; Shughrue, PJ | 1 |
| Bryant, HU; Cullinan, GJ; Dodge, JA; Glasebrook, AL; Grese, TA; Jones, CD; Matsumoto, K; Palkowitz, AD; Sato, M; Sluka, JP; Termine, JD; Winter, MA; Yang, NN | 1 |
| Benvenuti, S; Brandi, ML; Fiorelli, G; Formigli, L; Frediani, U; Gori, F; Martineti, V; Zecchi, S | 1 |
| Bryant, HU; Dere, WH | 1 |
| Boss, SM; Draper, MW; Eisenhut, CC; Glant, MD; Huster, WJ; Neild, JA | 1 |
| Adler, S; Sadovsky, Y | 1 |
| Allerheiligen, S; Baker, VL; Draper, M; Glant, M; Jaffe, RB; Paul, S; Shifren, J | 1 |
| Gustafsson, JA | 2 |
| Fitzpatrick, LA | 2 |
| Anthony, MS; Clarkson, TB; Jerome, CP | 1 |
| Adrian, MD; Bryant, HU; Cole, HW; Fuson, TR; Glasebrook, AL; Grese, TA; Magee, DE; Pennington, LD; Phillips, DL; Rowley, ER; Sato, M; Shetler, PK; Short, LL; Sluka, JP; Venugopalan, M; Yang, NN | 1 |
| Powles, TJ | 1 |
| Bush, TL; Cole, RC; Flaws, JA | 1 |
| Friedman, MN | 1 |
| Jordan, VC; Kwaan, HC; Levenson, AS; Svoboda, KM | 1 |
| Balfour, JA; Goa, KL | 1 |
| Jordan, VC; Levenson, AS | 1 |
| Nelson, NJ | 1 |
| Oliaro, A | 1 |
| Anderson, PW; Farmer, M; Kuller, LH; Lawrence, JB; Paul, S; Shah, AS; Walsh, BW; Wild, RA | 1 |
| Rifkind, BM; Rossouw, JE | 1 |
| Baynes, KC; Compston, JE | 1 |
| Dove, A | 1 |
| Gibbs, WW | 1 |
| Runowicz, C | 1 |
| Rossi, G | 1 |
| Davidson, NE; Hahm, HA; Nass, SJ | 1 |
| McNeil, C | 1 |
| Zaidi, M | 1 |
| Dere, WH | 1 |
| Amir-Zaltsman, Y; Jaffe, A; Knoll, E; Kohen, F; Somjen, D; Stern, N | 1 |
| Broy, S; Civitelli, R; Fleischmann, R; Gagel, R; Khosla, S; Lucas, M; Lukert, B; Maricic, M; Miller, P; Pacifici, R; Recker, R; Sarran, HS; Short, B; Short, MJ | 1 |
| Meier, CA | 1 |
| Bryant, HU; Cox, DA; Heath, H; Iversen, P; Kauffman, RF; Mitlak, BH | 1 |
| Funder, JW; Logie, C; Myles, K; Nichols, M; Stewart, AF | 1 |
| Schussheim, AE; Schussheim, DH | 1 |
| Cohen, FJ; Eckert, S; Mitlak, BH | 1 |
| Adrian, MD; Bryant, HU; Rowley, E; Sato, M; Turner, CH; Wang, T | 1 |
| Tonino, RP | 1 |
| Reynolds, T | 1 |
| Kupecz, D | 1 |
| Anderson, PW; Barrett-Connor, E; Collins, P; Cox, DA; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Wenger, NK | 2 |
| Argueta, R; Caplan, RH; Knickerbocker, RK; Lufkin, EG; Nickelsen, T; Riggs, BL; Whitaker, MD | 1 |
| Robb-Nicholson, C | 1 |
| Pérez, V; Suchecki, DE; Vilches, AR | 1 |
| Fuchs-Young, R; Nicosia, SV; O'Brien, WF; Porter, GW; Porter, KB; Spellacy, WN; Tsibris, JC | 1 |
| Agnusdei, D | 2 |
| de Valk-de Roo, GW; Jakobs, C; Kenemans, P; Mijatovic, V; Netelenbos, C; van der Mooren, MJ | 1 |
| Goldstein, SR | 2 |
| Mor, G; Naftolin, F; Nilsen, J | 1 |
| Overmoyer, BA | 1 |
| Heufelder, AE; Hofbauer, LC | 1 |
| Arcaro, KF; Brosch, K; Gierthy, JF; Seegal, RF; Spink, DC; Vakharia, DD; Yang, Y; Yi, L | 1 |
| Khovidhunkit, W; Shoback, DM | 1 |
| Chan, KW; Lim, HK; Sisenwine, S; Stellingweif, S | 1 |
| Gradishar, WJ; Jordan, VC; Morrow, M; Pierce, LJ; Takei, H | 1 |
| Cox, DA; Crook, TH; Lufkin, EG; Nickelsen, T; Riggs, BL | 1 |
| Duke, KM; Glasebrook, AW; Schmid, CR; Sluka, JP | 1 |
| Aron, ZD; Fink, BE; Katzenellenbogen, JA; Mortensen, DS; Stauffer, SR | 1 |
| McClung, BL | 1 |
| Delmas, PD; Fontana, A | 1 |
| Davies, GC; Huster, WJ; Lakshmanan, M; Lu, Y; Plouffe, L | 1 |
| Kardinal, CG; Veith, R | 1 |
| Brockie, J | 1 |
| Glasebrook, AL; Misner, JW; Schmid, CR; Stephenson, GA | 1 |
| Evans, MF; Park, L | 1 |
| Cohen, FJ; Mitlak, BH | 1 |
| Nishizawa, Y; Shioi, A | 1 |
| Jordan, VC; Morrow, M | 2 |
| de Valk-de Roo, GW; Kenemans, P; Mijatovic, V; Netelenbos, C; van der Mooren, MJ | 1 |
| Bjarnason, NH; Black, D; Cauley, JA; Costa, A; Cummings, SR; Eckert, S; Glusman, JE; Grady, D; Jordan, VC; Krueger, KA; Lippman, ME; Morrow, M; Nickelsen, T; Norton, L; Powles, TJ | 1 |
| Franks, AL; Steinberg, KK | 1 |
| O'Mahony, D | 1 |
| Carthew, P; Edwards, RE; Nolan, BM | 1 |
| Kenemans, P; Mijatovic, V; Netelenbos, JC; Stehouwer, CD; van der Mooren, MJ | 1 |
| Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB | 1 |
| Stephenson, J | 1 |
| Ullom-Minnich, P | 1 |
| Hochner-Celnikier, D | 1 |
| Kleerekoper, M | 1 |
| Frishman, WH; Goldfrank, D; Haytoglu, T; Mohammad, Z | 1 |
| Watts, NB | 1 |
| Anderson, P; Heath, H; Mitlak, B | 1 |
| MacReady, N | 1 |
| Dullaart, RP | 1 |
| Kuter, I | 1 |
| Jordan, VC; Liu, H; Schafer, JI; Tonetti, DA | 1 |
| Cohen, FJ; Davies, GC; Huster, WJ; Mitlak, B; Plouffe, L; Shah, A; Shen, W | 1 |
| Rubin, CD | 1 |
| Mattimoe, D; Newton, W | 1 |
| Apgar, B | 1 |
| Da Camara, CC; Early, JE; Scott, JA | 1 |
| Avioli, LV; Black, DM; Christiansen, C; Cohen, FJ; Cummings, SR; Delmas, PD; Eckert, S; Ensrud, KE; Ettinger, B; Genant, HK; Glüer, CC; Knickerbocker, RK; Krueger, K; Lips, P; Mitlak, BH; Nickelsen, T; Stakkestad, J; Zanchetta, JR | 1 |
| McClung, MR | 1 |
| Chapman, B | 1 |
| Galid, A; Kubista, E; Seifert, M | 1 |
| Cyr, M; Di Paolo, T; Landry, M; Morissette, M; Thibault, C | 1 |
| Sternon, J | 1 |
| Elit, L; Hirte, H | 1 |
| Gajdos, C; Jordan, VC | 1 |
| Bethea, CL; Michelson, D; Mirkes, SJ; Su, A | 1 |
| Candas, B; Couillard, S; Gutman, M; Labrie, C; Labrie, F; Roy, J | 1 |
| Chan, S | 1 |
| Amari, G; Armani, E; Caruso, PL; Civelli, M; Delcanale, M; Galbiati, E; Ghirardi, S | 1 |
| Cox, DA; Hurn, PD; Littleton-Kearney, MT; Ostrowski, NL; Rossberg, MI | 1 |
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Fried, A; Segev, E; Wientroub, S; Zeitlin, L | 1 |
| Anderson, DW; Bhagwat, SS; Brady, H; Gayo-Fung, LM; Leisten, J; Lipps, SG; McKie, JA; O'Leary, E; Patnaik, N; Stein, B; Sutherland, MK | 1 |
| Bhagwat, SS; Brady, H; Doubleday, M; Gayo, L; Hickman, M; Jalluri, RK; Khammungkhune, S; Kois, A; McKie, JA; Mortensen, D; Richard, N; Sapienza, J; Shevlin, G; Stein, B; Sutherland, M | 1 |
| Sporn, MB | 1 |
| Cummings, JL | 1 |
| David, E; Fournier dit Chabert, J; Lemaire, M; Pellet-Rostaing, S; Perrin, J | 1 |
| Johansen, AM | 1 |
| Armamento-Villareal, R; Brodt, MD; Caruso, PL; Civelli, M; Civitelli, R; Galbiati, E; Halstead, LR; Mueller, C; Napoli, N; Nawaz, A; Sheikh, S; Silva, MJ | 1 |
| Davis, AM; Ellersieck, MR; Grimm, KM; Rosenfeld, CS | 1 |
| Bolton, JL; Liu, H; Qin, Z; Thatcher, GR | 1 |
| Mukherjee, A; Mukherjee, S; Mullick, S; Nagar, S; Saha, A | 1 |
| Asghodom, RT; Bolton, JL; Frasor, J; Kastrati, I; Lantvit, DD; Overk, CR; Peng, KW; Qin, Z; Thatcher, GR | 1 |
| Bolton, JL; Dietz, BM; Dunlap, T; Kastrati, I; Lantvit, DD; Overk, CR; Qin, Z; Thatcher, GR; Yao, P; Yu, B | 1 |
| Davis, AM; Kohl, JA; Mao, J; Naz, B; Rosenfeld, CS | 1 |
| Azam, F; Chennathukuzhi, VM; Harris, HA; Huselton, C; Jelinsky, SA; Mekonnen, B; Negahban, A; Patel, VS; Schelling, SH; Winneker, RC; Zhang, X | 1 |
| Bolton, JL; Edirisinghe, P; Qin, Z; Thatcher, GR; Wijewickrama, GT; Yu, B | 1 |
| Cox, DA; Downs, RW; Dowsett, SA; Ghosh, A; Harper, K; Moffett, AM | 1 |
| Lewiecki, EM | 1 |
| Alam, J; Cox, DA; Dowsett, SA; Kendler, DL; Palacios, S; Stock, J; Zanchetta, J | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Alam, J; Bhattoa, HP; Cox, DA; Dowsett, SA; Goldstein, SR; Muram, D; Neven, P; Sipos, A | 1 |
| Gambhir, SS; Katzenellenbogen, JA; Massoud, TF; Paulmurugan, R; Tamrazi, A | 1 |
| Bolton, JL; Chandrasena, ER; Choi, J; Edirisinghe, PD; Hemachandra, LP; Kastrati, I; Thatcher, GR; Wang, YT | 1 |
| Belleau, P; Calvo, E; Labrie, F; Luu-The, V; Martel, C | 1 |
| Cuzick, J; Sestak, I | 1 |
| Bolton, JL; Chandrasena, RE; Choi, J; Hemachandra, LP; Michalsen, BT; Patel, H; Piyankarage, SC; Scism, RA; Siklos, MI; Thatcher, GR; Thayer, EN; Wang, S; Wang, Y; Xiong, R | 1 |
| Briarava, M; Mocellin, S; Nitti, D; Pilati, P | 1 |
| Allen, MR; Bivi, N; Burr, DB; Chalmers, MJ; Chavali, B; Dodge, JA; Durst, GL; Hu, H; Reutter, CT; Riley, A; Sato, M | 1 |
| Burdette, JE; Davis, DA; Dean, M; Moyle-Heyrman, G; Schipma, MJ | 1 |
| Knoll, E; Kohen, F; Limor, R; Many, A; Sharon, O; Somjen, D; Stern, N | 1 |
| Aldouby Bier, G; Cherniakov, I; Domb, AJ; Hoffman, A; Izgelov, D | 1 |
| Du, T; Etim, I; Gao, S; Hu, M; Liang, D; Sun, R; Zheng, Z | 1 |
51 review(s) available for raloxifene hydrochloride and piperidines
| Article | Year |
|---|---|
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Mammary Neoplasms, Experimental; Models, Biological; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Thiophenes | 1983 |
Alternate antiestrogens and approaches to the prevention of breast cancer.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Antagonists; Female; Humans; Liver Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Toremifene | 1995 |
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Topics: Animals; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1995 |
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
Topics: Adult; Blood Coagulation; Breast; Cardiovascular System; Endometrium; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Prospective Studies; Raloxifene Hydrochloride | 1996 |
Clinical potential of new antiestrogens.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene | 1997 |
Skeletal effects of estrogen analogs.
Topics: Bone and Bones; Estradiol Congeners; Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Gonadal hormone substitutes: effects on the cardiovascular system.
Topics: Animals; Coronary Disease; Coronary Vessels; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Selective estrogen receptor modulators and postmenopausal women's health.
Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Women's Health | 1997 |
Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Topics: Bone Resorption; Cholesterol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Uterus | 1998 |
Selective modulation of estrogen receptor action.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Menstrual Cycle; Ovulation; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
Status of antiestrogen breast cancer prevention trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States | 1998 |
Raloxifene.
Topics: Animals; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Osteoporosis; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 1998 |
Selective oestrogen receptor modulators: a new paradigm for HRT.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms | 1998 |
Management of postmenopausal osteoporosis for primary care.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Referral and Consultation; Risk Factors; Sodium Fluoride | 1998 |
Therapeutic potential of selective estrogen receptor modulators.
Topics: Animals; Clinical Trials as Topic; Drug Design; Estrogen Antagonists; Humans; Isoflavones; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Response Elements; Transcription Factor AP-1 | 1998 |
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Prognosis; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Vitamin D | 1998 |
Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene.
Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 1998 |
Selective estrogen receptor modulators and postmenopausal women's health: the promise for the next millennium.
Topics: Aged; Animals; Bone Density; Cardiovascular System; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Menopause; Middle Aged; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Approval; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Patient Selection; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States; United States Food and Drug Administration | 1999 |
Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene.
Topics: Animals; Breast Neoplasms; Crystallization; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Stimulation, Chemical; Tamoxifen | 1998 |
Clinical effects of raloxifene hydrochloride in women.
Topics: Animals; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1999 |
Current controversies in breast cancer management.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Patient Selection; Piperidines; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Using osteoporosis management to reduce fractures in elderly women.
Topics: Accidental Falls; Aged; Calcitonin; Calcium; Estrogen Antagonists; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Geriatric Assessment; Humans; Nutritional Physiological Phenomena; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Raloxifene Hydrochloride; Risk Factors | 1999 |
Prevention of breast cancer in high-risk women.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Incidence; Louisiana; Middle Aged; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 1999 |
Estrogen receptor as a target for the prevention of breast cancer.
Topics: Animals; Breast Neoplasms; Estrogen Antagonists; Humans; Meta-Analysis as Topic; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen | 1999 |
Development of a new prevention maintenance therapy for postmenopausal women.
Topics: Adult; Aged; Animals; Breast Neoplasms; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Rats; Tamoxifen | 1999 |
Selective estrogen receptor modulators: a look ahead.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Toremifene | 1999 |
[Estrogen receptor and selective estrogen receptor modulators (SERMs)].
Topics: Arteriosclerosis; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1999 |
Tamoxifen, raloxifene, and the prevention of breast cancer.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Tamoxifen | 1999 |
Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women.
Topics: Aged; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmenopausal; Phytoestrogens; Piperidines; Plant Preparations; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1999 |
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997.
Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Menopause; Osteoporosis; Phytoestrogens; Piperidines; Plant Preparations; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors | 1999 |
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Endothelium, Vascular; Estrogen Antagonists; Estrogens; Female; Hemostasis; Homocysteine; Hormone Replacement Therapy; Humans; Lipoprotein(a); Muscle, Smooth, Vascular; Piperidines; Progestins; Raloxifene Hydrochloride; Risk Factors | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D | 1999 |
Pharmacokinetics of raloxifene and its clinical application.
Topics: Adult; Aged; Aged, 80 and over; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Male; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1999 |
Clinical efficacy of raloxifene in postmenopausal women.
Topics: Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 1999 |
Raloxifene, a new selective estrogen receptor modulator.
Topics: Animals; Estrogen Antagonists; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1999 |
Postmenopausal osteoporosis.
Topics: Biomarkers; Bone Density; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Life Style; Mass Screening; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk Factors | 1999 |
Effect of raloxifene on the endometrium: will this be the ultimate key to its utilization?
Topics: Aged; Controlled Clinical Trials as Topic; Endometrium; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome | 1999 |
Treatment considerations in the management of age-related osteoporosis.
Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Severity of Illness Index | 1999 |
Raloxifene: a selective estrogen receptor modulator.
Topics: Bone and Bones; Clinical Trials as Topic; Drug Costs; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipids; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Teaching Materials; Uterus | 1999 |
[New drugs].
Topics: Amdinocillin; Carbamates; Clopidogrel; Cyclohexanes; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Patient Selection; Penicillins; Phenylalanine; Piperidines; Platelet Aggregation Inhibitors; Pneumococcal Vaccines; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Ticlopidine | 2001 |
Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Genes, Tumor Suppressor; Humans; Neoplasm Staging; Phosphoric Monoester Hydrolases; Piperidines; Progestins; PTEN Phosphohydrolase; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Survival Rate; Thiophenes; Tumor Suppressor Proteins | 2002 |
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome | 2002 |
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
Selective estrogen receptor modulators: tissue actions and potential for CNS protection.
Topics: Animals; Breast Neoplasms; Cardiovascular System; Central Nervous System; Cognition; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Hypothalamo-Hypophyseal System; Male; Neuroprotective Agents; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Neurotransmitter; Structure-Activity Relationship; Tamoxifen; Thiophenes; Uterus | 2002 |
Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Molecular Structure; Neoplasm Staging; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Thiophenes | 2004 |
Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Topics: Breast Neoplasms; Female; Humans; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2005 |
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2016 |
20 trial(s) available for raloxifene hydrochloride and piperidines
| Article | Year |
|---|---|
Antiestrogenic properties of raloxifene.
Topics: Adult; Analysis of Variance; Drug Interactions; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Luteinizing Hormone; Male; Middle Aged; Piperidines; Pituitary Hormones, Anterior; Prolactin; Raloxifene Hydrochloride; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone; Transcortin | 1995 |
A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Topics: Aged; Biomarkers; Biopsy; Double-Blind Method; Endometrium; Estrogen Antagonists; Estrogens; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Raloxifene Hydrochloride; Uterus | 1996 |
Raloxifene and estrogen: comparative bone-remodeling kinetics.
Topics: Bone Remodeling; Bone Resorption; Calcium; Creatinine; Estrogen Antagonists; Estrogens; Female; Humans; Hydroxyproline; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1997 |
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Topics: Bone Density; Cholesterol; Cholesterol, LDL; Double-Blind Method; Endometrium; Estrogen Antagonists; Female; Hip Joint; Hot Flashes; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1997 |
Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.
Topics: Biopsy; Double-Blind Method; Endometrium; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Stimulation, Chemical | 1997 |
Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles.
Topics: Adult; Chorionic Gonadotropin; Double-Blind Method; Endometrium; Estradiol; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Middle Aged; Ovulation; Piperidines; Prolactin; Raloxifene Hydrochloride; Random Allocation; Receptors, Estrogen; Vagina | 1998 |
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Topics: Aged; Analysis of Variance; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Piperidines; Postmenopause; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Risk Factors | 1998 |
Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.
Topics: Adult; Africa; Alkaline Phosphatase; Analysis of Variance; Australia; Biomarkers; Bone and Bones; Bone Remodeling; Collagen; Collagen Type I; Double-Blind Method; Estrogen Antagonists; Europe; Female; Humans; Hysterectomy; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Piperidines; Raloxifene Hydrochloride | 1998 |
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Chi-Square Distribution; Double-Blind Method; Estrogen Antagonists; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Spinal Fractures | 1998 |
Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
Topics: Administration, Oral; Animals; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Fasting; Female; Homocysteine; Horses; Humans; Hysterectomy; Middle Aged; Piperidines; Placebos; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Reference Values | 1998 |
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.
Topics: Adult; Affect; Aged; Cognition; Depression; Double-Blind Method; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Psychological Tests; Raloxifene Hydrochloride; Safety | 1999 |
Adverse events reported by postmenopausal women in controlled trials with raloxifene.
Topics: Adult; Aged; Breast Diseases; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Incidence; Middle Aged; Pain; Piperidines; Postmenopause; Raloxifene Hydrochloride; Uterine Hemorrhage | 1999 |
Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Topics: Bone Density; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Estrogen Antagonists; Estrogens; Evaluation Studies as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Raloxifene Hydrochloride; Time Factors | 1999 |
Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Topics: Administration, Oral; Analysis of Variance; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hysterectomy; Lipoprotein(a); Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome | 1999 |
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Topics: Aged; Breast Neoplasms; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Thromboembolism | 1999 |
Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Topics: Aged; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endometrium; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome | 1999 |
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Topics: Adult; Aged; Bone Density; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Radiography; Raloxifene Hydrochloride; Risk; Spinal Fractures | 1999 |
Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dose-Response Relationship, Drug; Double-Blind Method; Endometrium; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Vasomotor System | 2010 |
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Female; Femur Neck; Hip Joint; Hot Flashes; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Thiophenes; Treatment Outcome | 2012 |
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Topics: Aged; Aged, 80 and over; Endometrial Neoplasms; Endometrium; Female; Genital Diseases, Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Polyps; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Uterine Hemorrhage; Vaginitis; Vulvitis | 2012 |
206 other study(ies) available for raloxifene hydrochloride and piperidines
| Article | Year |
|---|---|
Estradiol regulates gonadotropin-releasing hormone receptor number, growth and inositol phosphate production in alpha T3-1 cells.
Topics: Animals; Cell Division; Cell Line; Corticosterone; Estradiol; Inositol Phosphates; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Receptors, LHRH; Signal Transduction; Testosterone; Up-Regulation | 1992 |
Effects of antiestrogens on adult and neonatal mouse reproductive organs.
Topics: Animals; Animals, Newborn; Body Weight; Clomiphene; Estrogen Antagonists; Female; Genitalia, Female; Genitalia, Male; Male; Mice; Mice, Inbred C57BL; Nafoxidine; Organ Size; Ovariectomy; Ovary; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Trifluoperazine; Uterus; Vagina | 1992 |
Lack of effectiveness of antiestrogens RU 39,411 or keoxifene in the prevention of estrogen-induced tumors in Syrian hamsters.
Topics: Animals; Cricetinae; Estradiol; Estrogen Antagonists; Kidney Neoplasms; Liver Neoplasms; Male; Mesocricetus; Piperidines; Raloxifene Hydrochloride; Testicular Neoplasms | 1992 |
Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Azasteroids; Dihydrotestosterone; DNA; Drug Therapy, Combination; Estrogen Antagonists; Female; Male; Mice; Mice, Inbred BALB C; Orchiectomy; Piperidines; Progesterone; Prostatic Hyperplasia; Raloxifene Hydrochloride; Urogenital System | 1990 |
Proliferation and differentiation of prepubertal mouse vaginal epithelial cells in vitro and the specificity of estrogen-induced growth retardation.
Topics: Animals; Cell Differentiation; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Estradiol; Estrogen Antagonists; Estrogens; Female; Mice; Mice, Inbred BALB C; Microscopy, Electron; Piperidines; Raloxifene Hydrochloride; Vagina | 1991 |
Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat.
Topics: Analysis of Variance; Androstenedione; Animals; Aromatase; Corpus Luteum; Diestrus; Estradiol; Estrogen Antagonists; Female; Gonadotropins, Equine; Luteinizing Hormone; Ovarian Follicle; Ovary; Piperidines; Proestrus; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Reference Values; Steroids; Testosterone | 1991 |
Tamoxifen-stimulated growth of human endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clomiphene; Enclomiphene; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Mice, Inbred BALB C; Nafoxidine; Neoplasm Transplantation; Piperidines; Polyunsaturated Alkamides; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms | 1991 |
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Topics: Androgens; Androstane-3,17-diol; Binding, Competitive; Cell Cycle; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Antagonism; Estradiol; Estrogen Antagonists; Estrone; Flow Cytometry; Flutamide; Humans; In Vitro Techniques; Male; Metribolone; Piperidines; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen; Testosterone; Time Factors; Tumor Cells, Cultured | 1991 |
Effect of estrogen inhibitors on conceptus estrogen synthesis and development in the gilt.
Topics: Acid Phosphatase; Androstenedione; Animals; Aromatase Inhibitors; Blastocyst; Calcium; Clomiphene; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Embryonic and Fetal Development; Estrogen Antagonists; Estrogens; Female; Least-Squares Analysis; Piperidines; Pregnancy; Pregnancy Proteins; Pregnancy, Animal; Pyrimidines; Raloxifene Hydrochloride; Swine | 1991 |
Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cattle; Cell Division; Contact Inhibition; Culture Media; Estradiol; Estrogens; Humans; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1991 |
Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells.
Topics: Androgens; Androstenediol; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dihydrotestosterone; Estrogens; Gene Expression; Glucocorticoids; Glycoproteins; Humans; In Vitro Techniques; Insulin; Medroxyprogesterone; Medroxyprogesterone Acetate; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured | 1990 |
The stimulation of uterine complement component C3 gene expression by antiestrogens.
Topics: Animals; Complement C3; Drug Interactions; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation; Kinetics; Nucleic Acid Hybridization; Piperidines; Progesterone; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; RNA, Messenger; Tamoxifen; Thiophenes; Uterus | 1990 |
Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors.
Topics: Animals; Danazol; Female; Flutamide; Luteinizing Hormone; Ovariectomy; Piperidines; Pregnadienes; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Androgen; Receptors, Estrogen | 1990 |
Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells.
Topics: Apolipoproteins; Apolipoproteins D; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Cell Division; Dexamethasone; Dihydrotestosterone; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Glycoproteins; Humans; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1990 |
Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Phenolphthaleins; Phenolsulfonphthalein; Piperidines; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains | 1990 |
Studies on the mechanism of action of danazol and gestrinone (R2323) in the rat: evidence for a masked estrogen component.
Topics: Animals; Danazol; Estrogen Antagonists; Estrogens; Female; Flutamide; Gestrinone; Keratins; Norpregnatrienes; Ovariectomy; Piperidines; Pregnadienes; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Progesterone; Testosterone; Uterus | 1989 |
Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
Topics: Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Epithelium; Estradiol; Estrogen Antagonists; Guinea Pigs; Male; Muscles; Orchiectomy; Organ Size; Piperidines; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Seminal Vesicles | 1989 |
Antiestrogen and antiandrogen administration reduce bone mass in the rat.
Topics: Androgen Antagonists; Animals; Bone Density; Bone Diseases, Metabolic; Cyproterone; Cyproterone Acetate; Estrogen Antagonists; Female; Hexestrol; Male; Orchiectomy; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Testosterone | 1989 |
Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Topics: Binding, Competitive; Breast Neoplasms; Cell Division; Dexamethasone; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Humans; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1989 |
Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain.
Topics: Animals; Drug Implants; Estrogen Antagonists; Estrogens; Female; Luteinizing Hormone; Median Eminence; Norepinephrine; Ovariectomy; Piperidines; Preoptic Area; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains | 1989 |
Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells.
Topics: Apolipoproteins; Apolipoproteins D; Blotting, Northern; Breast Neoplasms; Carrier Proteins; Cell Division; Dexamethasone; Dihydrotestosterone; DNA Probes; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Humans; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; RNA, Messenger | 1989 |
Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs.
Topics: Androstenediol; Androstenediols; Animals; Breast Neoplasms; Cells, Cultured; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Piperidines; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen | 1987 |
Actions and interactions of estradiol and retinoic acid in mouse anterior prostate gland.
Topics: Animals; Castration; Drug Interactions; Enzyme Activation; Estradiol; Glucosyltransferases; Male; Metaplasia; Mice; Nucleic Acids; Organ Size; Phosphoproteins; Phosphorylation; Piperidines; Prostate; Protein Kinases; Raloxifene Hydrochloride; Tretinoin | 1987 |
Hormonal modulation of macrophage clearance of IgG-sensitized cells.
Topics: Animals; Antigens, Differentiation; Erythrocytes; Estradiol; Estrogen Antagonists; Guinea Pigs; Immunoglobulin G; Macrophages; Male; Piperidines; Raloxifene Hydrochloride; Receptors, Fc; Receptors, IgG | 1987 |
Estrogen dependence of luteinizing hormone receptor expression in cultured rat granulosa cells. Inhibition of granulosa cell development by the antiestrogens tamoxifen and keoxifene.
Topics: Animals; Cells, Cultured; Cyclic AMP; Estradiol; Estrogen Antagonists; Estrogens; Female; Granulosa Cells; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Cell Surface; Receptors, LH; Tamoxifen | 1985 |
Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression.
Topics: Androstenedione; Animals; Aromatase Inhibitors; Cell Differentiation; Cells, Cultured; Cyclic AMP; Delayed-Action Preparations; Diethylstilbestrol; Estradiol; Estrogens; Female; Flutamide; Follicle Stimulating Hormone; Granulosa Cells; Oxidoreductases; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Cell Surface; Receptors, LH; Time Factors | 1985 |
Keoxifene (LY 156758) inhibits follicle-stimulating hormone induced differentiation of cultured rat granulosa cells.
Topics: Animals; Aromatase; Cell Differentiation; Cells, Cultured; Enzyme Induction; Estradiol; Female; Follicle Stimulating Hormone; Granulosa Cells; Kinetics; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, LH | 1987 |
Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.
Topics: Androgen Antagonists; Androstenedione; Breast Neoplasms; Cell Division; Cell Line; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Flutamide; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Testosterone | 1988 |
The lack of effect of phenol red or estradiol on the growth response of human, rat, and mouse mammary cells in primary culture.
Topics: Animals; Breast; Breast Neoplasms; Cell Division; Cells, Cultured; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Humans; Kinetics; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Phenolphthaleins; Phenolsulfonphthalein; Piperidines; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Lew; Receptors, Progesterone; Species Specificity; Tumor Cells, Cultured | 1988 |
Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary gonadotrophs.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Estradiol; Female; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Perfusion; Piperidines; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains | 1988 |
Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17 beta-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture.
Topics: Androgen Antagonists; Animals; Cell Division; Cell Line; Diethylstilbestrol; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Kinetics; Male; Mammary Neoplasms, Experimental; Mice; Piperidines; Raloxifene Hydrochloride; Receptors, Androgen; Testosterone | 1988 |
Phase II evaluation of Ly156758 in metastatic breast cancer.
Topics: Breast Neoplasms; Drug Evaluation; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Piperidines; Raloxifene Hydrochloride | 1988 |
Mechanisms subserving the bipotential actions of estrogen on ovarian cells: studies with a selective anti-estrogen, LY156758, and the sparingly metabolizable estrogen agonist, moxestrol.
Topics: 3-Hydroxysteroid Dehydrogenases; Animals; Dose-Response Relationship, Drug; Estradiol; Ethinyl Estradiol; Female; Ovary; Piperidines; Pregnenolone; Progesterone; Raloxifene Hydrochloride; Receptors, Estradiol; Swine | 1986 |
Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Hypothalamus, Middle; Piperidines; Posture; Progesterone; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Sexual Behavior, Animal; Tamoxifen | 1987 |
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Topics: Animals; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Time Factors; Uterus | 1987 |
An estrogen-dependent esterase activity in MCF-7 cells.
Topics: Breast Neoplasms; Cell Line; Esterases; Estradiol; Estrogens; Humans; Kinetics; Piperidines; Raloxifene Hydrochloride; Substrate Specificity | 1987 |
Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography.
Topics: Animals; Cell Division; Delayed-Action Preparations; DNA Replication; Drug Implants; Estradiol; Estrogen Antagonists; Female; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Ovariectomy; Piperidines; Raloxifene Hydrochloride | 1987 |
Effects of anti-estrogens on bone in castrated and intact female rats.
Topics: Animals; Body Weight; Bone and Bones; Estradiol; Estrogen Antagonists; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen | 1987 |
Synergistic actions of estradiol and the insulin-like growth factor somatomedin-C on swine ovarian (granulosa) cells.
Topics: Animals; Cells, Cultured; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Female; Granulosa Cells; Hydroxycholesterols; Insulin-Like Growth Factor I; Kinetics; Piperidines; Pregnenolone; Progesterone; Raloxifene Hydrochloride; Somatomedins; Swine | 1986 |
Estrogenic activity of phenol red in rat anterior pituitary cells in culture.
Topics: Animals; Cells, Cultured; Estradiol; Estrogens; Female; Luteinizing Hormone; Phenolphthaleins; Phenolsulfonphthalein; Piperidines; Pituitary Gland, Anterior; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen | 1986 |
Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Gonadotropin-Releasing Hormone; In Vitro Techniques; Luteinizing Hormone; Piperidines; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains | 1985 |
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Topics: Animals; Breast Neoplasms; Castration; Cell Division; Cell Line; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Piperidines; Progesterone; Raloxifene Hydrochloride; Tamoxifen | 1985 |
Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Castration; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Piperidines; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen | 1983 |
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1984 |
Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys.
Topics: Animals; Bile; Biological Availability; Chromatography, High Pressure Liquid; Dogs; Estrogen Antagonists; Feces; Female; Intestinal Absorption; Macaca mulatta; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Species Specificity | 1984 |
Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Thiophenes; Uterus | 1984 |
Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen.
Topics: Animals; Drug Antagonism; Estradiol; Female; Lactalbumin; Lactation; Macaca mulatta; Macaca nemestrina; Mammary Glands, Animal; Organ Culture Techniques; Piperidines; Pregnancy; Progesterone; Prolactin; Raloxifene Hydrochloride; Tamoxifen | 1983 |
Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Organ Size; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen; Thiophenes; Uterus | 1983 |
Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Hypertrophy; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Uterus | 1983 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fluorouracil; Incidence; Lung Neoplasms; Lymphatic Metastasis; Male; Organ Size; Piperidines; Prostate; Prostatic Neoplasms; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Survival Rate; Testis; Weight Gain | 1995 |
The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro.
Topics: Animals; Animals, Newborn; Bone Resorption; Calcitonin; Cells, Cultured; Centchroman; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Humans; Kinetics; Molecular Structure; Osteoclasts; Piperidines; Raloxifene Hydrochloride; Rats; Structure-Activity Relationship | 1995 |
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Topics: Animals; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Ethinyl Estradiol; Female; Humans; Middle Aged; Organ Size; Organ Specificity; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterus | 1995 |
Estrogen stimulation of galanin gene expression and galanin-like immunoreactivity in the rat and its blockade by the estrogen antagonist keoxifene (LY156758).
Topics: Adenoma; Animals; Chromatography, High Pressure Liquid; Estradiol; Estrogen Antagonists; Female; Galanin; Gene Expression Regulation; Gonadotropins, Equine; Hypothalamus; Neuropeptides; Peptide Biosynthesis; Peptides; Piperidines; Pituitary Gland, Anterior; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Inbred F344; Rats, Inbred WF; Rats, Sprague-Dawley; RNA, Messenger | 1993 |
Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Topics: Aging; Animals; Bone Density; Ethinyl Estradiol; Female; Lipids; Organ Size; Osteoporosis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Tomography, X-Ray Computed; Uterus | 1995 |
Raloxifene preserves bone strength and bone mass in ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Densitometry; Estrogens; Ethinyl Estradiol; Female; Femur Neck; Lumbar Vertebrae; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Time Factors; Uterus | 1994 |
Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Femur; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reproducibility of Results | 1994 |
The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Development; Bone Resorption; Cell Count; Cholesterol; Female; Organ Size; Osteoclasts; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Uterus | 1994 |
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Female; Humans; Models, Biological; Piperidines; Point Mutation; Raloxifene Hydrochloride; Receptors, Estrogen; Transfection; Tumor Cells, Cultured | 1993 |
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Topics: Aldehyde-Lyases; Androgens; Animals; Binding, Competitive; Cholestenone 5 alpha-Reductase; Cytochrome P-450 Enzyme System; Estrogen Antagonists; Hypothalamo-Hypophyseal System; Male; Oxidoreductases; Piperidines; Pituitary-Adrenal System; Prostate; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Steroid 17-alpha-Hydroxylase; Testosterone | 1993 |
Antioestrogen inhibits myelination in brains of juvenile Zebra finches.
Topics: Animals; Birds; Brain; Estrogen Antagonists; Male; Myelin Sheath; Neurons; Piperidines; Raloxifene Hydrochloride | 1993 |
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; Calcium; Cholesterol; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Estrogen Antagonists; Ethinyl Estradiol; Female; Hypertrophy; Ovariectomy; Phosphorus; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Triglycerides; Uterus | 1994 |
Role of aromatization in testosterone-induced inhibition of luteinizing hormone secretion in female turtles, Trachemys scripta.
Topics: Androstenedione; Animals; Aromatase; Aromatase Inhibitors; Brain; Estrogen Antagonists; Fadrozole; Feedback; Female; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Ovariectomy; Ovary; Piperidines; Pituitary Gland; Raloxifene Hydrochloride; Testosterone; Turtles | 1994 |
Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tretinoin | 1996 |
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.
Topics: Animals; Cell Line; Chlorocebus aethiops; DNA; Estradiol; Estrogen Antagonists; Gene Expression Regulation; Kidney; Molecular Structure; Piperidines; Polyunsaturated Alkamides; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Proteins; Structure-Activity Relationship; Tamoxifen; Transfection | 1995 |
Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Phosphorylation; Piperidines; Raloxifene Hydrochloride; Receptor, IGF Type 1; Tamoxifen; Tumor Cells, Cultured; Tyrosine | 1996 |
Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Topics: Animals; Base Sequence; Bone and Bones; Cell Differentiation; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation; Molecular Sequence Data; Osteoclasts; Ovariectomy; Piperidines; Promoter Regions, Genetic; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transfection; Transforming Growth Factor beta | 1996 |
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Topics: Adipose Tissue; Animals; Bone Density; Estrogen Antagonists; Estrogens; Female; Lipid Metabolism; Nafoxidine; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reproduction; Tamoxifen; Uterus | 1996 |
Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene.
Topics: Base Sequence; Estradiol; Estrogen Antagonists; Gene Expression Regulation; Genes, Reporter; Humans; Ligands; Molecular Sequence Data; Piperidines; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 1996 |
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene | 1996 |
Drug's link to genes reveals estrogen's many sides.
Topics: Bone and Bones; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Transforming Growth Factor beta; Uterus | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Estrogen Antagonists; Ethinyl Estradiol; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 1996 |
Estrogen and bone: new pieces to the puzzle.
Topics: Animals; Bone Resorption; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Mice; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor beta | 1996 |
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Estrogens; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Uterus | 1996 |
Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones.
Topics: Calcitriol; Creatine Kinase; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Osteoblasts; Piperidines; Plasmids; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Recombinant Proteins; Stimulation, Chemical; Tamoxifen; Teriparatide; Tumor Cells, Cultured | 1996 |
Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL).
Topics: Animals; Antioxidants; Copper; Dexamethasone; Estradiol; Estrogen Antagonists; Free Radicals; Horseradish Peroxidase; Humans; Lipoproteins, LDL; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Oxidation-Reduction; Peroxidase; Phagocytosis; Piperidines; Probucol; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Thiobarbituric Acid Reactive Substances; Thiophenes; Tyrosine | 1996 |
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms | 1996 |
Failure of cannabinoid compounds to stimulate estrogen receptors.
Topics: Breast Neoplasms; Cannabinoids; Cell Division; Dronabinol; Estrogens; Humans; Phenanthridines; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Transcriptional Activation; Tumor Cells, Cultured | 1997 |
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
Topics: Animals; Anticholesteremic Agents; Cholesterol, HDL; Dose-Response Relationship, Drug; Female; Male; Organ Specificity; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen | 1997 |
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Topics: Adenocarcinoma; Animals; Binding Sites; Bone and Bones; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Female; Humans; Male; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1997 |
Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Topics: Adipocytes; Age Factors; Animals; Anticarcinogenic Agents; Biomarkers; Bone and Bones; Cartilage; Cells, Cultured; Creatine Kinase; Dose-Response Relationship, Drug; Embryo, Mammalian; Epiphyses; Estradiol; Estrogen Antagonists; Female; Humans; Isoenzymes; Male; Osteoblasts; Piperidines; Puberty; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tamoxifen; Uterus | 1996 |
Correction: raloxifene response needs more than an element.
Topics: Estrogen Antagonists; Gene Expression Regulation; Humans; Piperidines; Promoter Regions, Genetic; Raloxifene Hydrochloride; Transforming Growth Factor beta | 1997 |
Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
Topics: Animals; Cholesterol; Dexamethasone; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogens; Ethinyl Estradiol; Female; Fulvestrant; Lipids; Ovariectomy; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1997 |
Estrogen receptor ligands modulate its interaction with DNA.
Topics: DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Fulvestrant; Humans; Ligands; Piperidines; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcription Factors | 1997 |
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Diethylstilbestrol; DNA Nucleotidyltransferases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Hexestrol; HSP90 Heat-Shock Proteins; Humans; Ligands; Molecular Sequence Data; Nafoxidine; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Time Factors; Yeasts | 1997 |
Osteoporosis drugs show early promise.
Topics: Bone Density; Estrogen Antagonists; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Next generation of SERMs being seen in clinic.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1997 |
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
Topics: Administration, Oral; Animals; Benzopyrans; Binding, Competitive; Breast Neoplasms; Cytosol; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Molecular Structure; Ovariectomy; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Uterus | 1997 |
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1997 |
Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
Topics: Administration, Oral; Animals; Estrogen Antagonists; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Uterus | 1997 |
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured | 1997 |
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Topics: Animals; Bone and Bones; Bone Density; Cinnamates; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Stilbenes; Tamoxifen; Tumor Cells, Cultured; Uterus | 1997 |
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
Topics: Animals; Breast Neoplasms; Cell Line; Diethylstilbestrol; Enhancer Elements, Genetic; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; HeLa Cells; Humans; Ligands; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Uterus | 1997 |
Designer oestrogens: fact or fantasy?
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Raloxifene Hydrochloride | 1997 |
Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Estrogen Antagonists; Female; Organ Size; Ovariectomy; Piperidines; Rabbits; Raloxifene Hydrochloride; Uterus; Weight Gain | 1997 |
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
Topics: Adenocarcinoma; Animals; Bone Resorption; Breast Neoplasms; Cell Division; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Glucuronates; Humans; Interleukin-6; Organ Specificity; Osteoclasts; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tissue Distribution; Transforming Growth Factor beta; Tumor Cells, Cultured | 1997 |
Molecular basis of agonism and antagonism in the oestrogen receptor.
Topics: Binding Sites; Crystallography, X-Ray; Estradiol; Estrogen Antagonists; Humans; Models, Molecular; Piperidines; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen | 1997 |
Picture story. Agony and antagonism.
Topics: Binding Sites; Estrogen Antagonists; Estrogens; Models, Molecular; Piperidines; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen | 1997 |
Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
Topics: Alkaline Phosphatase; Carcinoma, Hepatocellular; Clone Cells; Estradiol; Estradiol Congeners; Estrogen Antagonists; Ethinyl Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Kinetics; Liver Neoplasms; Piperidines; Placenta; Pregnancy; Protein Biosynthesis; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Sex Hormone-Binding Globulin; Tamoxifen; Tetradecanoylphorbol Acetate; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1997 |
Tissue-specific estrogens--the promise for the future.
Topics: Bone Density; Cholesterol; Endometrium; Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen | 1997 |
Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study.
Topics: Animals; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; In Situ Hybridization; Piperidines; Preoptic Area; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Progesterone; RNA, Messenger; Sensitivity and Specificity; Tamoxifen; Time Factors | 1997 |
Molecular determinants of tissue selectivity in estrogen receptor modulators.
Topics: Animals; Cell Line; Estradiol Congeners; Estrogen Antagonists; Female; Ligands; Models, Molecular; Molecular Conformation; Piperidines; Protein Conformation; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen; Thermodynamics; Tissue Distribution; Uterus | 1997 |
Heterogeneity of binding sites and bioeffects of raloxifene on the human leukemic cell line FLG 29.1.
Topics: Apoptosis; Binding Sites; Binding, Competitive; Cell Division; Cell Nucleus; Cytosol; Dithiothreitol; DNA Fragmentation; Electrophoresis, Agar Gel; Estradiol; Filaggrin Proteins; Humans; Leukemia, Monocytic, Acute; Microscopy, Electron; Osteoclasts; Piperidines; Promegestone; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 1997 |
Raloxifene: magic bullet for heart and bone?
Topics: Bone and Bones; Cholesterol, LDL; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type.
Topics: Adult; Aged; Bone Density; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Coronary artery disease in women--an equal opportunity killer.
Topics: Animals; Coronary Disease; Estrogens; Female; Humans; Male; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Sex Distribution | 1998 |
Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
Topics: Animals; Coronary Artery Disease; Coronary Vessels; Diet, Atherogenic; Estradiol; Estrogens; Female; Horses; Lipids; Lipoproteins; Macaca fascicularis; Osmolar Concentration; Ovariectomy; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1998 |
'Smart' estrogens emerging.
Topics: Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Research | 1998 |
New drug approved to help prevent osteoporosis.
Topics: Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Raloxifene for postmenopausal osteoporosis.
Topics: Bone Density; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Thromboembolism | 1998 |
New estrogen may hold greater appeal.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1998 |
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Topics: Animals; Bone Density; Cell Division; Cholesterol; Estrogen Antagonists; Female; Gene Expression Regulation; HeLa Cells; Humans; Models, Molecular; Molecular Conformation; Naphthoquinones; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Transforming Growth Factor beta; Tumor Cells, Cultured; Uterus | 1998 |
Effects of raloxifene in postmenopausal women.
Topics: Bone Density; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Research Design | 1998 |
Effects of raloxifene in postmenopausal women.
Topics: Affect; Estrogen Antagonists; Female; Humans; Memory; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Piperidines; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Topics: Aspartic Acid; Blotting, Northern; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Mutagenesis, Site-Directed; Piperidines; Point Mutation; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1998 |
Anti-estrogens come of age: a pioneer looks back.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms | 1998 |
[Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
Topics: Adult; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1998 |
Of designer drugs, magic bullets, and gold standards.
Topics: Cardiovascular Diseases; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Humans; Piperidines; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 1998 |
Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
Topics: BRCA2 Protein; Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Genes, BRCA1; Genetic Testing; Humans; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transcription Factors | 1998 |
Selective oestrogen receptor modulators: potential therapeutic applications.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
The prevention pill.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
A new alternative to estrogen: raloxifene.
Topics: Bone Density; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Clear thinking on tamoxifen.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
[Current trends in prevention and therapy of postmenopausal osteoporosis].
Topics: Animals; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Rats; Time Factors | 1998 |
Breast cancer biology blossoms in the clinic.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Tamoxifen; Trastuzumab | 1998 |
Until there's more information, caution advised in using tamoxifen or raloxifene for breast cancer prevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
In search of the perfect SERM: beyond tamoxifen and raloxifene.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1998 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Clinical efficacy of SERMs.
Topics: Aged; Bone Density; Estrogen Antagonists; Estrogens; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells.
Topics: Analysis of Variance; Androgen Antagonists; Antibodies, Monoclonal; Cell Division; Cell Line; Cells, Cultured; Creatine Kinase; Dihydrotestosterone; DNA; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Flutamide; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Microscopy, Fluorescence; Muscle, Smooth, Vascular; Piperidines; Platelet-Derived Growth Factor; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thymidine | 1998 |
Role of novel antiresorptive agents for the prevention and treatment of osteoporosis.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
Topics: Animals; Coronary Artery Disease; Estrogen Antagonists; Female; Macaca fascicularis; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1998 |
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
Topics: Diethylstilbestrol; Dimerization; DNA Nucleotidyltransferases; Estradiol; Estrogen Antagonists; Fulvestrant; Hexestrol; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen | 1998 |
New hope for prevention, treatment of breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
Smart estrogens may decrease heart-attack risk.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Heart Diseases; Humans; Lipids; Piperidines; Raloxifene Hydrochloride | 1998 |
Is digoxin a designer oestrogen?
Topics: Designer Drugs; Digoxin; Estrogen Antagonists; Humans; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1998 |
LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Cholesterol; Estrogen Antagonists; Female; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Thiophenes; Uterus | 1998 |
Designer estrogens.
Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen | 1998 |
Tamoxifen debate hinges on whose risk is high enough.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Estrogen Antagonists; Female; Humans; Physician's Role; Piperidines; Raloxifene Hydrochloride; Risk; Tamoxifen | 1998 |
Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
Topics: Adult; Aged; Bone Density; Drug Interactions; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a
Topics: Alendronate; Colonic Diseases, Functional; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Raloxifene-associated hepatitis.
Topics: Bone Density; Chemical and Drug Induced Liver Injury; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1998 |
Effects of raloxifene in a guinea pig model for leiomyomas.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Guinea Pigs; Leiomyoma; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Ultrasonography; Uterine Neoplasms | 1998 |
Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women.
Topics: Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1998 |
Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells.
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Nerve Growth Factors; Neurites; PC12 Cells; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction | 1998 |
Tamoxifen for prevention of breast cancer.
Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis | 1999 |
[Raloxifene].
Topics: Adult; Contraindications; Controlled Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Pregnancy; Raloxifene Hydrochloride | 1999 |
2,2',6,6'-Tetrachlorobiphenyl is estrogenic in vitro and in vivo.
Topics: Animals; Binding, Competitive; Estradiol; Estrogens; Female; Humans; Molecular Structure; Organ Size; Piperidines; Polychlorinated Biphenyls; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tumor Cells, Cultured; Uterus | 1999 |
Evista and the brain.
Topics: Brain; Cells, Cultured; Estrogen Antagonists; Estrogens; Female; Humans; Neurites; Piperidines; Raloxifene Hydrochloride | 1999 |
Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding.
Topics: Animals; Autoanalysis; Biotransformation; Chromatography, Liquid; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Pharmaceutical Preparations; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Drug; Structure-Activity Relationship; Tamoxifen | 1999 |
Coronary heart disease in women, randomized clinical trials, HERS and RUTH.
Topics: Coronary Disease; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Meta-Analysis as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Women's Health | 1998 |
Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.
Topics: Binding, Competitive; Carbon; Cell Division; Cell Line; Crystallography, X-Ray; Humans; Oxygen; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship | 1999 |
Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens.
Topics: Binding Sites; Estradiol; Estrogen Antagonists; Estrogens; Imidazoles; Isoxazoles; Ligands; Models, Molecular; Oxazoles; Piperidines; Protein Conformation; Pyrazoles; Raloxifene Hydrochloride; Receptors, Estrogen; Thiazoles; X-Ray Diffraction | 1999 |
[Bone and hormones. Estrogens and antiestrogens: action on osteoporosis].
Topics: Aged; Clinical Trials, Phase III as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipids; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Tamoxifen; Time Factors | 1999 |
Using SERMS for treating postmenopausal symptoms.
Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Topics: Binding, Competitive; Cell Division; Dose-Response Relationship, Drug; Estrogen Antagonists; Models, Molecular; Piperidines; Raloxifene Hydrochloride; Tumor Cells, Cultured | 1999 |
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5: Selective estrogen receptor modulators and hormone replacement therapy. Proceedings of a conference. Charlottesville, Virginia, USA. September 21-23, 1997.
Topics: Antineoplastic Agents; Bone Density; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Menopause; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors; Tamoxifen | 1999 |
Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
Topics: Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Prevention of corticosteroid-induced osteoporosis and fractures.
Topics: Adrenal Cortex Hormones; Bone Density; Calcitonin; Calcitriol; Calcium Channel Agonists; Estrogen Antagonists; Fractures, Bone; Hormone Replacement Therapy; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1999 |
Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Topics: Animals; Anticarcinogenic Agents; Bromodeoxyuridine; Cell Division; Cell Nucleus; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogens; Female; Hypertrophy; Mice; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Uterus; Vagina | 1999 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity | 1999 |
Experts debate drugs for healthy women with breast cancer risk.
Topics: Adult; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietary Supplements; Estrogen Replacement Therapy; Estrogens; Exercise; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Risk Factors; Smoking Cessation; Vitamin D | 1999 |
Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1999 |
Update in endocrinology.
Topics: Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Risk | 1999 |
Raloxifene reduces spinal fractures postmenopausally.
Topics: Adult; Aged; Aged, 80 and over; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Spinal Fractures | 1999 |
Exogenous estrogens, antiestrogens and lipid metabolism.
Topics: Anticholesteremic Agents; Contraindications; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hyperlipidemia, Familial Combined; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Breast cancer highlights.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Neoplasm Staging; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 1999 |
Designer estrogens: breast cancer benefit, remaining questions.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1999 |
The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Topics: Benzopyrans; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |
Does raloxifene reduce breast cancer risk?
Topics: Aged; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Incidence; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 1999 |
Is raloxifene the answer to the HRT story?
Topics: Bone and Bones; Breast Neoplasms; Cardiovascular System; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Humans; Patient Education as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; United States | 1999 |
Therapy for fracture prevention.
Topics: Bone Density; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Lipids; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1999 |
The oestrogen receptor and its selective modulators in gynaecological oncology.
Topics: Antineoplastic Agents, Hormonal; Cinnamates; Estrogen Antagonists; Female; Genital Neoplasms, Female; Humans; Norpregnenes; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thiophenes; Toremifene | 2000 |
Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain.
Topics: Animals; Brain; Estradiol; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Ovariectomy; Phenols; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tamoxifen | 2001 |
Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.
Topics: Animals; Carrier Proteins; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Gene Expression; Macaca mulatta; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Nerve Tissue Proteins; Piperidines; Raloxifene Hydrochloride; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; RNA, Messenger; Selective Estrogen Receptor Modulators; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Tryptophan Hydroxylase | 2002 |
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Topics: Animals; Breast Neoplasms; Cell Division; Cell Size; Cinnamates; Endometrium; Epithelial Cells; Estrogen Antagonists; Estrone; Female; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Stilbenes; Tamoxifen; Toremifene; Tumor Cells, Cultured | 2002 |
Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Benzopyrans; Bone Density; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Molecular Structure; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Uterus | 2002 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice.
Topics: Adipose Tissue; Animals; Body Weight; Bone Marrow Cells; Cholesterol; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Fish Oils; Hypolipidemic Agents; Interleukin-1; Interleukin-10; Interleukin-6; Mice; Mice, Inbred BALB C; Ovariectomy; Ovary; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Skin; Spleen; Thiophenes; Triglycerides; Tumor Necrosis Factor-alpha | 2003 |
Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Topics: Administration, Oral; Animals; Body Weight; Bone Density; Bone Resorption; Cholesterol; Coumarins; Dose-Response Relationship, Drug; Female; Femur; Organ Size; Ovariectomy; Piperidines; Radiography; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Triglycerides; Uterus | 2003 |
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
Topics: Animals; Binding Sites; Coumarins; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Interleukin-6; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured | 2004 |
Searching for methods to detect, prevent, and treat Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Female; Humans; Indans; Magnetic Resonance Spectroscopy; Occipital Lobe; Piperidines; Predictive Value of Tests; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2005 |
Efficient access to 2-aryl-3-substituted benzo[b]thiophenes.
Topics: Cyclization; Molecular Structure; Oxidation-Reduction; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Thiophenes | 2005 |
A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Benzopyrans; Biomechanical Phenomena; Blood; Body Composition; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Cholesterol; Compressive Strength; Estrogen Receptor Modulators; Ethinyl Estradiol; Female; Femur; Femur Neck; Lumbar Vertebrae; Organ Size; Osteoclasts; Osteogenesis; Ovariectomy; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Tibia; Tomography, X-Ray Computed; Triglycerides; Uterus; Weight-Bearing | 2005 |
The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Topics: Animals; Apoptosis; Body Weight; Cell Line, Tumor; Endometrial Neoplasms; Endometrium; Estrogen Receptor alpha; Estrogen Receptor beta; Female; In Situ Nick-End Labeling; Mice; Mice, Knockout; Organ Size; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sheep; Uterus | 2006 |
Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene.
Topics: Alkylation; Animals; Catalysis; Female; Glutathione; Horseradish Peroxidase; Indolequinones; Microsomes; Piperidines; Quinones; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Thiophenes; Uterus | 2007 |
Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches.
Topics: Animals; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Molecular; Piperidines; Quantitative Structure-Activity Relationship; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Thiophenes | 2008 |
Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Topics: Animals; Female; Lipids; Organ Size; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Thiophenes; Uterus | 2007 |
Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
Topics: Animals; Antioxidants; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoprevention; Female; Humans; Liver; Liver Neoplasms; Luciferases; Mice; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Peroxides; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes; Tumor Cells, Cultured | 2007 |
Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.
Topics: Animals; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Mice; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Pyrazoles; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Uterus | 2008 |
Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats.
Topics: Animals; Biomarkers; Brain; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Naphthalenes; Ovarian Cysts; Ovary; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Steroid 17-alpha-Hydroxylase; Up-Regulation | 2008 |
Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics.
Topics: Animals; Azides; Biotinylation; Cell Extracts; Cell Line, Tumor; Hepatocytes; Indicators and Reagents; Ligands; Mass Spectrometry; Oxidation-Reduction; Piperidines; Proteins; Quinones; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Staining and Labeling; Thiophenes; Xenobiotics | 2009 |
In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterodimerization: exploration of new modes of receptor regulation.
Topics: Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation; Genes, Reporter; HEK293 Cells; Humans; Luciferases, Firefly; Luciferases, Renilla; Mice; Mice, Nude; Molecular Imaging; Piperidines; Protein Multimerization; Protein Stability; Protein Structure, Tertiary; Pyrazoles; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transplantation, Heterologous | 2011 |
Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Biomarkers; Breast; Catechols; Cell Line; Cell Transformation, Neoplastic; Cytochrome P-450 Enzyme System; Deoxyguanosine; DNA Adducts; Enzyme Induction; Epithelial Cells; Estrogens; Female; Histone Deacetylase Inhibitors; Horses; Humans; Oxidation-Reduction; Oxidative Stress; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes | 2011 |
Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.
Topics: Animals; Cluster Analysis; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Genes; Genes, Neoplasm; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome | 2012 |
Preventive therapy for breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Topics: Cell Transformation, Neoplastic; Cells, Cultured; Cytoprotection; Estradiol; Humans; Inactivation, Metabolic; Indoles; Mammary Glands, Human; MCF-7 Cells; Oxidants; Oxidative Stress; Piperidines; Raloxifene Hydrochloride; Reactive Oxygen Species; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Up-Regulation | 2014 |
Structural features underlying raloxifene's biophysical interaction with bone matrix.
Topics: Animals; Bone Matrix; Collagen; Dogs; Durapatite; Femur; Hydrophobic and Hydrophilic Interactions; Male; Piperidines; Polylysine; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Static Electricity; Structure-Activity Relationship; Thiophenes | 2016 |
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma in Situ; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fallopian Tubes; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thiophenes; Transcriptome | 2016 |
Estradiol-17β increases 12- and 15-lipoxygenase (type2) expression and activity and reactive oxygen species in human umbilical vascular smooth muscle cells.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavanones; Gene Expression Regulation; Humans; Hydroxyeicosatetraenoic Acids; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidases; Nitriles; Phenols; Piperidines; Primary Cell Culture; Propionates; Pyrazoles; Pyrimidines; Raloxifene Hydrochloride; Reactive Oxygen Species; RNA, Messenger; Umbilical Veins | 2016 |
The Effect of Piperine Pro-Nano Lipospheres on Direct Intestinal Phase II Metabolism: The Raloxifene Paradigm of Enhanced Oral Bioavailability.
Topics: Administration, Oral; Alkaloids; Animals; Benzodioxoles; Biological Availability; Chemistry, Pharmaceutical; Drug Delivery Systems; Emulsions; Excipients; Intestines; Lipids; Male; Metabolic Detoxication, Phase II; Nanoparticles; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Rats; Rats, Wistar | 2018 |
Age-and Region-Dependent Disposition of Raloxifene in Rats.
Topics: Age Factors; Animals; Biological Availability; Female; Glucuronates; Glucuronosyltransferase; Intestines; Liver; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred F344 | 2021 |